Clinical Trial Update: Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

View source ↗

Summary

A clinical study update for a PET imaging agent (18F-HER2 Affibody) evaluating HER2-expression in breast cancer; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 18F-HER2 Affibody PET tracer (18F-labeled HER2-binding Affibody molecule)

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: Breast Cancer, Breast Cancer, HER2-Expression | Status: RECRUITING